



Network Oncology Inc. Lists On Frankfurt Stock Exchange and Begins Trading Under New Symbol 2NY: FSX and WKN#: A11827

Vancouver, B.C., February 5, 2015 – Network Oncology Inc. (“Network”, “the Company”) has completed its Frankfurt listing and has begun trading on the Deutsche Boerse Xetra - Frankfurt Stock Exchange on or about, January 28, 2015 under the new symbol 2NY, (ISIN:CA64130A1066, WKN#: A11827). The Company’s shares will trade in Euros on this stock exchange.

The Frankfurt Stock Exchange is the world's third largest trading center for securities and Germany's largest exchange. It is responsible for ninety percent of the securities trading volume in Germany. Controlled by Deutsche Boerse, owner of the European Futures Exchange (Eurex) and the clearing company Clearstream, Frankfurt's is the largest stock exchange in Germany. Through the Xetra platform, the Exchange facilitates advanced electronic trading, settlement and information systems and enables cross-border trading for international investors. The website for the Frankfurt Stock exchange is located at:

<http://www.boerse-frankfurt.de/en/start#&reiter=ipo>

Sean Maenpaa, CEO of Network Oncology states, “Our Company is developing a broad portfolio of oncology generics which is initially centered within the German market. Coupled with being able to trade our stock on a major stock exchange in Germany will only further increase European investor interest and understanding of our business practices and strategies”.

Further Information

Further details are available under the Company’s profile on SEDAR at www.sedar.com, and the Company’s profile on the CSE’s website at www.cnsx.ca.

For further information please contact:
Sean Maenpaa, President, CEO, and Director
Telephone: +353(0)874601340
E-mail: info@networkoncology.com
Website: www.networkoncology.com

About Network Oncology Inc. Network has acquired and is currently selling a core portfolio of oncology generic products for the European markets with possible expansion to other territories. The Company is commercially focussed and is dedicated to serving the oncology marketplace by understanding local market dynamics and its customers unmet needs. In addition, the Company has the ability to identify and pursue profitable segments of the oncology market in conjunction with providing value-added products and support services for its portfolio. Network also possesses the knowledge and capability to develop and commercialize differentiated versions of existing cancer products where an unmet need currently exists.

Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Network. Forward-looking information is based on certain key expectations and assumptions made by the management of Network, including future plans for the distribution of oncology products. Although Network believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Network can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. Network disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

NOTE: This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.